Coherus BioSciences Inc (NAS:CHRS)
$ 1.78 0.02 (1.14%) Market Cap: 204.21 Mil Enterprise Value: 423.31 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 42/100

Coherus BioSciences Inc at JPMorgan Healthcare Conference Transcript

Jan 10, 2024 / 05:45PM GMT
Release Date Price: $2.86 (-4.03%)
Chris Scott JPMorgan Chase;Co.;Moderator

&-

Good morning, everybody. I'm Chris Schott at JPMorgan, and it's my pleasure to be introducing Coherus this morning. From the company, we have Denny Lanfear, President and CEO, who is going to make some opening remarks, and we're going to jump into a Q&A session from there with the broader management team. So that happened to you, Denny, and over to you.

Dennis M. Lanfear Coherus BioSciences
Inc. - President & CEO

Thank you.

Chris, and thank you once again for having us at the conference this year. Let me first, of course, apprise you of the forward-looking statements, which will address issues with the revenue projections, product development, time lines, the various assets, the future of those products and so on. And then we, of course, refer you to the Company's regulatory filings. So today, what I'd like to do is, first of all, give you a flyby summary of the Company. We've made substantial progress on our strategy of moving to an oncology company. We are revenue stage

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot